New CEO picked to run Theraclone; XenoPort suspends investment in Parkinson's drug; Peregrine shares spike on tumor data;

 @FierceBiotech: Biogen Idec signs up with Samsung on $300 million biosimilars venture. News | Follow @FierceBiotech

 @JohnCFierce: Sustained release levodopa/carbidopa (xenoport) fails Ph2 Parkinson's study. Does anyone really understand this field? Report | Follow @JohnCFierce

 @RyanMFierce: Sanofi's GLP-1 drug yields upbeat data in pivotal study in T2DM. GLP-1 class growing beyond Byetta/Bydureon, Victoza. Item | Follow @RyanMFierce

 @FierceMedDev: Randox's new molecular diagnostic test permits quick selection of colorectal cancer patients for Anti-EGFR therapy. Release | Follow @FierceMedDev

> It may have taken a bit longer than initially expected planned, but Theraclone Sciences founder Steve Gillis has found a CEO to helm the company. Clifford Stocks was named CEO of the biotech, a 2011 Fierce 15 company. Stocks is the former chief business officer at Calistoga, which was acquired earlier this year by Gilead in a $600 million deal. Release

> XenoPort said it would suspend any further investments in its experimental Parkinson's drug until the company had a chance to find out what went wrong in the latest study. Investigators report that the drug--XP21279, a sustained release form of the standard therapy Sinemet--performed only slightly better than Sinemet in the study. Story

> Peregrine Pharmaceuticals' badly battered shares spiked 40% this morning after the biotech announced new data demonstrating that its bavituximab antibody combined with chemo improved the tumor response rate in lung cancer patients. Story

> Gilead Sciences ($GILD) says that cobicistat--an HIV therapy booster added to several new cocktail treatments--performed at least as well as Abbott's ($ABT) Norvir in a 96-week study. Report

> Cell Therapeutics says that the FDA has given itself an April 24 deadline to complete its second look at the experimental cancer drug pixantrone. The FDA rejected the drug last year after roasting the Seattle biotech's clinical trial data. Story

> Numerate has signed a pact with Boehringer Ingelheim to use its drug design technology to find new drug candidates for an undisclosed infectious disease target. Release

Pharma News

 FiercePharma: FDA weighs Teva's request to bring Plan B contraceptive out from behind the pharmacists' counter. News | Follow@FiercePharma

> Study: Bigger fines needed to ward off marketing misbehavior. News

> Want Europeans' attention? Use websites, not Twitter, study finds. Report

> Ex-FDA chief: Bayer held back Yasmin safety info. Article

Biotech Research News

> Partial, lab-grown pituitary gland works in mice. News

> Gene may hold back skin, head, neck cancers. Story

> Researchers unmask protein as villain in pancreatic, brain cancer growth. Item

> Search is on for new anti-addiction drug targets. Article

> Adult stem cell pathway could yield better muscle disorder treatments. Report

Manufacturing News

> Pfizer presence unmistakable in 1940s Brooklyn. News

> MA anticipates bioprocess job increase. Item

> Theravance MRSA drug a victim of Ben Venue shutdown. Report

> Issue separates bio, small molecule CMOs. News

> Online vaccines available from suspect sources. Article

And Finally... After decades spent in disrepute, investigators are once more attempting to learn the therapeutic benefits offered by hallucinogens. Article

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.